UBS raised the firm’s price target on Insmed (INSM) to $194 from $140 and keeps a Buy rating on the shares. The firm is adding in additional Brinsupri indications to its model. The firm expects rapid uptake of Brinsupri in non-cystic fibrosis bronchiectasis patients and tells investors in a research note that Insmed is well-positioned to execute on the launch as the sales force was deployed approximately 10 months prior to launch, engaging with physicians on disease education.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Promising Growth Prospects: Buy Rating Driven by Brinsupri’s Blockbuster Potential and Strategic Market Positioning
- Private Markets: AI model startup Reflection AI raises $2B
- Insmed price target raised to $193 from $154 at TD Cowen
- Insmed’s TPIP Shows Promising Phase 2 Results, Boosting Buy Rating and Future Prospects
- Insmed price target raised to $180 from $110 at Evercore ISI